A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate

Sánchez-Felipe, Lorena; Vercruysse, Thomas; Sharma, Sapna; Ma, Ji; Lemmens, Viktor; Looveren, Dominique Van; Javarappa, Mahadesh Prasad Arkalagud; Boudewijns, Robbert; Malengier‐Devlies, Bert; Kaptein, Suzanne F; Liesenborghs, Laurens; Keyzer, Carolien De; Bervoets, Lindsey; Rasulova, Madina; Seldeslachts, Laura; Jansen, S.L.; Yakass, Michael Bright; Quaye, Osbourne; Li, Li-Hsin; Zhang, Xin; Horst, Sebastiaan ter; Mishra, Niraj; Coelmont, Lotte; Cawthorne, Christopher; Laere, Koen Van; Opdenakker, Ghislain; Velde, Greetje Van de; Weynand, Birgit; Teuwen, Dirk E.; Matthys, Patrick; Neyts, Johan; Thibaut, Hendrik Jan; Dallmeier, Kai

doi:10.1101/2020.07.08.193045

Cited by 17 publications

(15 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The neutralizing antibody levels rose significantly after the booster vaccination reaching a PRNT80 geometric mean titer (GMT) of 207 and PRNT50 GMT of 761 that are comparable or exceeding titers of other DNA vaccines evaluated in nonhuman primates 13 and mice 18 . The PRNT50=761 is similar to the 50% titers elicited in hamsters vaccinated with single-dose, live-virus vectored vaccines: Ad26-vectored vaccine PsVNA50 <1000; VSV-vectored vaccine PRNT50 <1000, and Yellow Fever-vectored vaccine PRNT50 <1000 [7][8][9] . Neutralization titer was plotted against viral RNA detected in lung tissue collected at the time of euthanasia.…”

Section: Discussionsupporting

confidence: 52%

See 1 more Smart Citation

Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters

Brocato

Kwilas

Kim

et al. 2020

Preprint

View full text Add to dashboard Cite

A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages of research and development, including several vaccines in phase 1, 2 and 3 clinical trials. A relatively small number of these vaccines have been evaluated in SARS-CoV-2 disease models, and fewer in a severe disease model. Here, a SARS-CoV-2 DNA targeting the spike protein and delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies in hamsters and was protective in both wild-type and transiently immunosuppressed hamster models. This study highlights the DNA vaccine, nCoV-S(JET), we developed has a great potential to move to next stage of preclinical studies, and it also demonstrates that the transiently-immunosuppressed Syrian hamsters, which recapitulate severe and prolonged COVID-19 disease, can be used for preclinical evaluation of the protective efficacy of spike-based COVID-19 vaccine.

show abstract

Section: Discussionsupporting

confidence: 52%

“…Histopathology includes areas of lung consolidation, followed by pneumocyte hyperplasia as the virus is cleared. At least three candidate vaccines have been tested for efficacy in the Syrian hamster model [7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters

Brocato

Kwilas

Kim

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Histopathological analysis of infected hamsters shows multifocal interstitial pneumonia characterized by pulmonary consolidation starting as early as 2 dpi. Inflammation is associated with leukocyte infiltration, comprised primarily of macrophages and neutrophils, and an increase in type I and III interferon (IFN) and other pro-inflammatory cytokine and chemokines [14, 15]. High-resolution computed tomography scans shows airway dilation and consolidation in the lungs of infected hamsters [10].…”

Section: Introductionmentioning

confidence: 99%

A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

Bricker

Hassan

Harastani

et al. 2020

Preprint

View full text Add to dashboard Cite

The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable or neutralizing the virus, antibody levels in serum were higher in hamsters immunized by an intranasal compared to intramuscular route. Accordingly, ChAd-SARS-CoV-2-S immunized hamsters were protected against a challenge with a high dose of SARS-CoV-2. After challenge, ChAd-SARS-CoV-2-S-immunized hamsters had less weight loss and showed reductions in viral RNA and infectious virus titer in both nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.

show abstract

“…Two of the influenza-based candidates are designed for intranasal administration. A live attenuated yellow fever vector-based vaccine (YFS0) expressing the prefusion form of the S protein recently showed that a single dose protected most hamsters in a SARS-CoV-2 challenge model ( 109 ).…”

Section: Different Vaccine Approaches Used In Covid-19 Vaccine Develomentioning

confidence: 99%

Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines

et al. 2020

View full text Add to dashboard Cite

There are currently around 200 SARS-CoV-2 candidate vaccines in preclinical and clinical trials throughout the world. The various candidates employ a range of vaccine strategies including some novel approaches. Currently, the goal is to prove that they are safe and immunogenic in humans (phase 1/2 studies) with several now advancing into phase 2 and 3 trials to demonstrate efficacy and gather comprehensive data on safety. It is highly likely that many vaccines will be shown to stimulate antibody and T cell responses in healthy individuals and have an acceptable safety profile, but the key will be to confirm that they protect against COVID-19. There is much hope that SARS-CoV-2 vaccines will be rolled out to the entire world to contain the pandemic and avert its most damaging impacts. However, in all likelihood this will initially require a targeted approach toward key vulnerable groups. Collaborative efforts are underway to ensure manufacturing can occur at the unprecedented scale and speed required to immunize billions of people. Ensuring deployment also occurs equitably across the globe will be critical. Careful evaluation and ongoing surveillance for safety will be required to address theoretical concerns regarding immune enhancement seen in previous contexts. Herein, we review the current knowledge about the immune response to this novel virus as it pertains to the design of effective and safe SARS-CoV-2 vaccines and the range of novel and established approaches to vaccine development being taken. We provide details of some of the frontrunner vaccines and discuss potential issues including adverse effects, scale-up and delivery.

show abstract

A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate

Cited by 17 publications

References 54 publications

Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters

Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters

A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines

Contact Info

Product

Resources

About